Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Current approaches and challenges in the molecular therapeutic targeting of glioblastoma.

Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, Nakano I.

World Neurosurg. 2019 May 29. pii: S1878-8750(19)31482-2. doi: 10.1016/j.wneu.2019.05.205. [Epub ahead of print] Review.

PMID:
31152883
2.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

3.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

4.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

5.

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.

Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N.

Neuro Oncol. 2018 Mar 27;20(4):506-518. doi: 10.1093/neuonc/nox182.

6.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
7.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
8.

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.

Carter TC, Medina-Flores R, Lawler BE.

Biomed Res Int. 2018 Dec 31;2018:6204676. doi: 10.1155/2018/6204676. eCollection 2018.

9.

Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.

Jindal V.

Mol Neurobiol. 2018 Nov;55(11):8236-8242. doi: 10.1007/s12035-018-0978-z. Epub 2018 Mar 9. Review.

PMID:
29524050
10.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

11.

Targeting role of glioma stem cells for glioblastoma multiforme.

Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ.

Curr Med Chem. 2013;20(15):1974-84. Review.

PMID:
23317162
12.

Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.

Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, Shan C, Xie X, Li D, Zhan X, Li C, Li XF, Qin X, Zhao T, Wu H, Shi PY, Man J, Qin CF.

MBio. 2018 Sep 18;9(5). pii: e01683-18. doi: 10.1128/mBio.01683-18. Erratum in: MBio. 2019 Apr 2;10(2):. Zhao, Tongyang [corrected to Zhao, Tongyan].

13.

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.

14.

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Prinzing BL, Gottschalk SM, Krenciute G.

Expert Rev Anticancer Ther. 2018 May;18(5):451-461. doi: 10.1080/14737140.2018.1451749. Epub 2018 Mar 16. Review.

15.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

16.

Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.

Kim JS, Shin DH, Kim JS.

J Control Release. 2018 Jan 10;269:245-257. doi: 10.1016/j.jconrel.2017.11.026. Epub 2017 Nov 21.

PMID:
29162480
17.

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.

Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Namba H, Mori K, Tomiyama A.

Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Review.

18.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
19.

Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.

Jahan N, Lee JM, Shah K, Wakimoto H.

Int J Cancer. 2017 Oct 15;141(8):1671-1681. doi: 10.1002/ijc.30811. Epub 2017 Jul 19.

20.

Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.

Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li S.

Cancer Lett. 2018 Oct 1;433:176-185. doi: 10.1016/j.canlet.2018.07.008. Epub 2018 Jul 6.

PMID:
29991446

Supplemental Content

Support Center